TARS

Tarsus Pharmaceuticals Stock Price

25.43
-0.31 (-1.2%)
Upgrade to Real-Time
Regular Market
25.43

Low
17.96

52 Week Range

High
63.69

Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
Small Cap Basic
Monthly Subscription
for only
$33.03
Big Cap Pro
Monthly Subscription
for only
$52.04
VAT not included
Company Name Stock Ticker Symbol Market Type
Tarsus Pharmaceuticals Inc TARS NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.31 -1.2% 25.43 11:15:05
Open Price Low Price High Price Close Price Prev Close
25.67 24.9888 26.50 25.74
Bid Price Ask Price Spread News
25.45 26.51 1.06 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
122 5,918 $ 25.74 $ 152,315 - 17.96 - 63.69
Last Trade Time Type Quantity Stock Price Currency
11:15:05 1 $ 25.56 USD

Period:

Draw Mode:

Tarsus Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 521.94M 20.52M 8.80M $ - $ - -4.52 -6.80
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 111.01k 7.50%

more financials information »

Tarsus Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical TARS Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week26.1526.5324.7825.7237,505-0.72-2.75%
1 Month30.0130.849924.7828.2950,841-4.58-15.26%
3 Months29.9139.0824.7830.4472,761-4.48-14.98%
6 Months40.6342.7024.7831.4752,340-15.20-37.41%
1 Year18.3063.6917.9634.1670,5417.1338.96%
3 Years18.3063.6917.9634.1670,5417.1338.96%
5 Years18.3063.6917.9634.1670,5417.1338.96%

Tarsus Pharmaceuticals Description

Tarsus Pharmaceuticals Inc is a late clinical-stage biopharmaceutical company. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's lead candidate TP-03, is a novel drug that targets the Demodex mite nervous system to kill the mites.


Your Recent History
NASDAQ
TARS
Tarsus Pha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.